PALI

Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its clinical pipeline. R&D expenses rose to $6.4 million for the quarter, compared to $1.0 million in Q1 2025, driven by higher employee-related costs, chemistry, manufacturing, and controls/CMC expenses, and clinical trial costs for PALI-2108. G&A expenses also increased to $4.4 million, up from $1.4 million in the prior year’s period, due to higher professional fees and non-cash share-based compensation. The company highlighted the continued clinical progress of its lead candidate, PALI-2108, a once-daily, orally administered PDE4 inhibitor prodrug designed for targeted delivery to the terminal ileum and colon to treat inflammatory bowel disease/IBD. Following positive Phase 1a/b data in ulcerative colitis/UC, Palisade Bio reported encouraging data from its Phase 1b fibrostenotic Crohn’s disease cohort. The results showed sustained active metabolite exposure above necessary thresholds, favorable distribution to colon tissue, and modulation of key inflammatory and fibrotic pathways. Palisade Bio Inc. (NASDAQ:PALI) plans to submit an IND application for a Phase 2 UC trial in Q2, aiming for trial initiation in Q3 and a primary efficacy readout in H2 2027. Additionally, an IND submission for a Phase 2 Crohn’s disease trial is expected in H2 2026, targeting trial initiation in Q1 2027 and a primary efficacy readout in early 2028. Palisade Bio Inc. (NASDAQ:PALI) is a biopharmaceutical company. While we acknowledge the potential of PALI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations. Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications. The data demonstrated sustained exposure of the active metabolite above IC90 thresholds, along with favorable distribution to colon tissue, supporting consistent target engagement at the site of disease. In addition, pharmacodynamic findings showed modulation of key inflammatory and fibrotic pathways, reinforcing the potential of PALI-2108 to address both components of IBD. The program continues to demonstrate a favorable safety and tolerability profile, reinforcing confidence in the potential of PALI-2108 as it advances into Phase 2 development. “We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” said JD Finley, Chief Executive Officer of Palisade Bio. “The totality of data generated to date supports our decision to advance into Phase 2 development in both ulcerative colitis and Crohn’s disease. With consistent target engagement, evidence of activity across key inflammatory and fibrotic pathways, and a favorable safety profile, we are increasingly confident in the potential of PALI-2108 as we move into development this year.” Recent Highlights and Anticipated Milestones Completed Phase 1a/b for PALI-2108, Reported Positive Data Favorable safety and tolerability profile Evidence of target engagement in ileal and colon...

We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday. Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for its treatment of fibrostenotic Crohn’s disease (FSCD). The company is targeting to present the topline results of its Phase 1b study of PALI-2108 in the first quarter of 2026, with the Investigational New Drug submission expected in the first half of next year. The first phase enrolled approximately 6 to 12 patients with FSCD, and was designed to evaluate the efficacy of PALI-2108 over a 14-day treatment period. Results aside, the rally in Palisade Bio Inc. (NASDAQ:PALI) can also be attributed to some window-dressing activities—a practice among institutional investors where they tweak their portfolios before reporting periods, typically done quarterly and annually, by loading up on well-performing stocks and trimming those that underperform, to perform a stronger portfolio for clients. Year-to-date, Palisade Bio Inc.’s (NASDAQ:PALI) shares were up by 33.33 percent. Palisade Bio Inc. (NASDAQ:PALI) is a clinical-stage biopharmaceutical company advancing a next generation of once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases. While we acknowledge the potential of PALI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

VANCOUVER, BC, Aug. 28, 2025 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") is pleased to announce that at its meeting ("Meeting") of shareholders (the "Shareholders") held yesterday Shareholders approved the re-election of Gregor Gregersen and Elizabeth Harrison to the Board of Directors of the Company (the "Board"). In addition, Collin Kettell and Philip O'Neill were elected to the Board. Former director and Chief Financial Officer Bassam Moubarak did not stand for re-election. Effective immediately, Mr. O'Neill will also serve as the Company's Chief Operating Officer. Also during the Meeting, Shareholders approved the proposed return of capital transaction (the "Transaction") as announced in the news release dated July 24, 2025. The Transaction remains subject to receipt of the final order (the "Final Order") by the British Columbia Supreme Court (the "Court"), approval of the TSX Venture Exchange ("TSXV"), and completion of required regulatory filings. The Company will announce the effective date of the Transaction once all necessary approvals have been obtained. All other matters put forward before the Shareholders at the meeting for consideration and approval, including the re-appointment of Deloitte LLP, Chartered Professional Accountants, as auditor of the Company at a remuneration to be fixed by the Board, renewal of the stock option plan of the Company, the grant of conditional stock options under the Company's stock option plan, as well as the potential creation of Michael Parker as a new Control Person, as such term is defined in the polices of the TSXV, of the Company, all as set out in the Company's Management Information Circular dated July 21, 2025, were approved. Philip O'Neill Mr. O'Neill is an experienced mining executive and corporate director. He is currently the President and founder of MP1 Capital, a Calgary based investment company created to focus on the natural resources sector. Mr. O'Neill was Director and Chief Operating Officer of Palisades Goldcorp Ltd. from 2019 to 2021, during which Palisades Goldcorp Ltd. became one of the most active financiers in the junior mining space. In 2010, Mr. O'Neill founded TSX listed Sunward Resources Ltd. ("Sunward") where he held the positions of CEO and Director, raising $81 million in a 10-month span to advance the Titiribi gold/copper project in Colombia. In 2015,...

Palisade Bio (PALI) shares were up 3% in recent Thursday trading after the company disclosed "positi

Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here. The Phase 1 program, which included single ascending dose (SAD), multiple ascending dose (MAD), and cross-over food effect (FE) studies in adult healthy volunteers, as well as a small cohort of UC patients, successfully met its primary endpoints of safety, tolerability, and pharmacokinetics (PK). The data support progression into Phase 2 development. “These data validate PALI-2108’s targeted prodrug design and provide compelling evidence that the drug reaches therapeutic concentrations in the colon with lower systemic exposure,” said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio. “The observed tissue penetration of the active drug and the absence of serious adverse events, together with our significant body of nonclinical PK data, support our confidence in advancing PALI-2108 into patient-focused trials for fibrostenotic Crohn’s disease and ulcerative colitis.” Key Phase 1 Findings Safety & Tolerability: No serious adverse events (SAEs) or laboratory/EKG-related adverse events were observed across SAD, MAD and FE cohorts. In the SAD study (15–450 mg), only mild and reversible treatment-emergent AEs (TEAEs) occurred, limited to the highest dose (450 mg). MAD cohorts (15, 30, and 50 mg BID over 7 days, as well as 30 mg titrated over 7 days) showed mostly minor TEAEs and most often at...